<mods:mods version="3.3" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd" xmlns:mods="http://www.loc.gov/mods/v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><mods:titleInfo><mods:title>METABOLIC SYNDROME IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: CLINICAL FEATURES, METABOLIC DISORDERS AND APPROACHES TO CORRECTION</mods:title></mods:titleInfo><mods:name type="personal"><mods:namePart type="given">Amonova N</mods:namePart><mods:namePart type="family">Amonova N</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:name type="personal"><mods:namePart type="given">Umurova N</mods:namePart><mods:namePart type="family">Umurova N</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:abstract>Metabolic syndrome (MS) combined with type 2 diabetes mellitus (T2DM) is one of the most urgent global health problems. It represents a cluster of metabolic and cardiovascular disorders such as abdominal obesity, hypertension, hyperglycemia, dyslipidemia, and insulin resistance [1–3]. The coexistence of MS and T2DM markedly increases the risk of cardiovascular events, nephropathy, and non-alcoholic fatty liver disease. According to IDF and WHO data, the prevalence of MS among diabetic patients reaches 60–80%, emphasizing the need for comprehensive therapeutic strategies to improve metabolic control and prevent complications.</mods:abstract><mods:originInfo><mods:dateIssued encoding="iso8601">2025-10-30</mods:dateIssued></mods:originInfo><mods:genre>Maqola</mods:genre></mods:mods>